Skip to main content

Table 4 Mean difference and 95% CI over time compared to baseline

From: Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial

Measure

Delta Baseline to Time 1

Delta Baseline to Time 2

 

Control

Treatment

Control

Treatment

VAS-1st Position (mm)

 Unadjusted*

−14 (− 21 to −7)

−4 (− 10 to 2)

−14 (− 23 to −5)

− 5 (− 14 to 5)

 Adjusted**a, b

−15 (− 22 to − 7)

−4 (− 10 to 3)

−16 (− 26 to −6)

−2 (− 12 to 8)

VAS-2nd Position (mm)

 Unadjusted*

−13 (− 21 t0–5)

−5 (− 11 to 1)

−16 (− 26 to − 6)

−7 (− 16 to 2)

 Adjusted** b, c

−13 (− 22 to − 5)

−6 (− 12 to 0)

−19 (− 30 to − 8)

− 7 (− 16 to 3)

VAS-PDA (mm)

 Unadjusted*

−25 (− 56 to 5)

−22 (− 41 to − 2)

− 44 (− 79 to − 9)

−16 (− 39 to 6)

 Adjusted** a, c

− 21 (− 55 to 12)

−18 (− 36 to 1)

−40 (− 79 to − 1)

− 15 (− 40 to 10)

PEFR (L/min)

 Unadjusted*

4 (−12 to 19)

− 10 (− 25 to 4)

4 (− 13 to 20)

− 6 (− 21 to 10)

 Adjusted** b, d

5 (− 10 to 21)

− 11 (− 26 to 3)

7 (− 9 to 23)

−5 (− 20 to 10)

NT-proBNP (ng/ml)

 Unadjusted*

0.03 (−0.16 to 0.23)

−0.11 (− 0.23 to 0.02)

−0.15 (− 0.28 to − 0.02)

−0.15 (− 0.30 to − 0.01)

 Adjusted** c

−0.03 (− 0.14 to 0.07)

−0.14 (− 0.27 to − 0.01)

−0.14 (− 0.27 to − 0.02)

−0.16 (− 0.31 to − 0.002)

FFA (mEq/ml)

 Unadjusted*

0.22 (0.11 to 0.32)

0.18 (0.07 to 0.30)

0.16 (0.05 to 0.27)

0.24 (0.13 to 0.35)

 Adjusted** a, b

0.23 (0.12 to 0.35)

0.17 (0.05 to 0.30)

0.16 (0.03 to 0.28)

0.23 (0.11 to 0.35)

Glucose (mg/dl)

 Unadjusted*

−45 (−70 to − 21)

−43 (− 73 to − 14)

−48 (− 72 to − 24)

−38 (− 64 to − 13)

 Adjusted**

−42 (− 65 to − 18)

−44 (− 74 to − 14)

−44 (− 67 to − 21)

−37 (− 63 to − 11)

  1. Values are mean difference and Sidak adjusted 95% Confidence Intervals
  2. *Includes design variables: site, diabetes medication (self-report) and NT-proBNP quartile
  3. **Additional adjustments for: baseline values of the outcome, thiamine, BMIa, LVEF> = 50% b, PEFR c, systolic BP d